Magda M. Hagras

Magda M. Hagras

Auto-generated profile, based on publicly available information

Magda M. Hagras

Pharmacology department, Faculty of Medicine, Suez Canal University, Egypt

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2016 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
RMRama I. Mahran
Rama I. Mahran
MHMagda M. Hagras
Magda M. Hagras
DSDuxin Sun
Duxin Sun
DBDean E. Brenner
Dean E. Brenner

18 April 2019 in African Health Sciences
Verified
Journal Article
Open access
PDF file
RNRania A Najdi
Rania A Najdi
MHMagda M Hagras
Magda M Hagras
FKFatemah O Kamel
Fatemah O Kamel
RMRania M Magadmi
Rania M Magadmi
A randomized controlled clinical trial evaluating the effect of Trigonella foenum-graecum (fenugreek) versus glibenclamide in patients with diabetes

1 November 2017 in Complementary Therapies in Clinical Practice
Verified
Journal Article
Closed access
FKFatemah O. Kamel
Fatemah O. Kamel
RMRania M Magadmi
Rania M Magadmi
MHMagda M. Hagras
Magda M. Hagras
BMBashair Magadmi
Bashair Magadmi
RAReem A. AlAhmad
Reem A. AlAhmad

17 October 2012 in Journal of the Renin-Angiotensin-Aldosterone System
Verified
Journal Article
Closed access
PDF file
DADaad H Akbar
Daad H Akbar
MHMagda M Hagras
Magda M Hagras
HAHanan A Amin
Hanan A Amin
OKOmayma A Khorshid
Omayma A Khorshid
Hypothesis: This study aimed to elucidate the role of glibenclamide in the prevention of diabetic nephropathy and to compare it with a reference drug captopril in rats. Materials and methods: There were two main groups of rats. Control group (I) was subdivided into four subgroups which received distilled water, vehicle of streptozotocin, glibenclamide or captopril. The streptozotocin-diabetic Group (II) was subdivided into three subgroups: untreated, glibenclamide or captopril treated. Measurement of arterial blood pressure, serum glucose and creatinine levels, 24 h urinary protein and albumin/creatinine ratio, kidney weight and its histological examination were done after 1, 2, 4, 8, 12 and 16 weeks of treatment. Results: In treated diabetic rats captopril reduced blood pressure significantly, while no significant change in the mean arterial blood pressure or blood glucose level was recorded with glibenclamide treatment. Glibenclamide and captopril-treated diabetic rats showed significant decrease in serum creatinine level, urine volume, urinary protein excretion, albumin:creatinine ratio and kidney:body weight ratio compared with the diabetic non-treated group. Histological examination of diabetic kidneys treated with either glibenclamide or captopril showed reduced glomerular hypertrophy, glomerulosclerosis, tubular degeneration and interstitial fibrosis compared with untreated diabetic rats. Conclusion: Glibenclamide attenuated some biochemical and histological changes produced by diabetic nephropathy, despite persistent hyperglycemia and hypertension.

1 February 2019 in Pharmacological Reports
Verified
Journal Article
Closed access
RERefaat I. ElFayoumi
Refaat I. ElFayoumi
MHMagda M. Hagras
Magda M. Hagras
AAAdel Abozenadaha
Adel Abozenadaha
MGMamdouh Gari
Mamdouh Gari
IAIbrahim Abosoudah
Ibrahim Abosoudah
WBWaleed Bawazir
Waleed Bawazir

27 April 2018 in Medical Teacher
Verified
Journal Article
Closed access
FKFatemah O. Kamel
Fatemah O. Kamel
HAHebah A. Alwafi
Hebah A. Alwafi
MAMariyyah A. Alshaghab
Mariyyah A. Alshaghab
ZAZahrah M. Almutawa
Zahrah M. Almutawa
LALana A. Alshawwa
Lana A. Alshawwa
ATAra Tekian
Ara Tekian
Purpose: Prescription errors are a common cause of adverse drug events (ADEs). Recognizing ADEs can significantly contribute to the reduction of morbidity and mortality. This study aims to investigate the type and prevalence of errors in prescription writing, directed toward a needs assessment for developing educational interventions. Materials and methods: A cross-sectional descriptive study was conducted in Jeddah community pharmacies (January–February 2016). A random sample of 117 prescriptions were reviewed and analyzed by community pharmacists for legibility and omission of the information in the prescription. Results: Results revealed that 51% of the prescriptions included diagnosis, in which 62% included the recommended drug dosage. Only 7% of drug interactions were reported between the prescribed drugs, 17% of the physicians prescribed drugs that prevented the adverse effects used for diagnosis. Prescriptions for chronic conditions were scrutinized to be 18%. It was noteworthy that 29% of the pharmacists reported difficulty in reading the handwriting of prescriptions. Conclusions: The quality of prescription writing is deficient in some elements and strategies for improvement are needed. These findings underscore a crucial requirement to upgrade the quality of prescription writing by encouraging continuous medical education programs to facilitate delivery of excellent therapeutic outcomes.